GOBLET: A phase 1/2 multiple indication study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – preliminary safety and efficacy results in second-line or later unresectable anal carcinoma
Arnold, Dirk et al. Previously presented at The 2nd International Multidisciplinary Anal Cancer Conference (IMACC) 2023, Nov. 9-10, 2023